Drug Trial Radar · NCT01583218
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Last checked: Nov 19, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,513
Actual
Start
Mar 2012
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Portola PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.
Conditions
- Venous Thromboembolism (VTE)
Interventions
BetrixabanDrug
Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days. Enoxaparin Placebo: Once daily, 6-14 days
EnoxaparinDrug
Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days. Betrixaban Placebo: once daily, 35 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT Cohort 1: Between randomization and Day 47 (max)
- mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT Cohort 2: Between randomization and Day 47 (max)
- mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3Time frame: mITT: Between randomization and Day 47 (max)
- Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study MedicationTime frame: Between randomization and Day 49 (max)
Locations
462 sites in 34 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Bakersfield, California
Site not named
Fresno, California
Site not named
La Mesa, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Modesto, California
Site not named
San Diego, California
Site not named
Stanford, California
Site not named
Torrance, California
Site not named
Englewood, Colorado
Site not named
Bay Pines, Florida
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Pensacola, Florida
Site not named
Sarasota, Florida
Site not named
Vero Beach, Florida
Site not named
Columbus, Georgia
Site not named
Decatur, Georgia
Site not named
Chicago, Illinois
Site not named
Oak Park, Illinois
Site not named
Carmel, Indiana
Site not named
Davenport, Iowa
Site not named
Windsor Heights, Iowa
Site not named
Topeka, Kansas
Site not named
Hazard, Kentucky
Site not named
Annapolis, Maryland
Site not named
Baltimore, Maryland
Site not named
Detroit, Michigan
Site not named
Grand Blanc, Michigan
Site not named
Royal Oak, Michigan
Site not named
Troy, Michigan
Site not named
Duluth, Minnesota
Site not named
Picayune, Mississippi
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Butte, Montana
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Showing 40 of 462 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.